Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Birabresib in Advanced Solid Tumors
NCT02259114Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of birabresib in NUT carcinoma (NMC), triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC) and 2 more (2 arms), sponsored by Merck & Co. Primary endpoint: Dose Limiting Toxicity. Started Oct 2014; status: completed.
02
Drugs
birabresib
03
Conditions
NUT carcinoma (NMC)triple-negative breast cancer (TNBC)non-small cell lung cancer (NSCLC)castration-resistant prostate cancer (CRPC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02259114.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02259114.